Report Sections

See All Reports

Coronavirus Infections (808) Severe Acute Respiratory Syndrome (560) Infection (466) Pneumonia (365) Communicable Diseases (197) Respiratory Distress Syndrome, Adult (178) Acute Lung Injury (143) Respiratory Distress Syndrome, Newborn (143) (130) Syndrome (105) Virus Diseases (87) Pneumonia, Viral (82) Depression (65) Critical Illness (62) Anxiety Disorders (38) Respiratory Tract Infections (36) Cardiovascular Diseases (35) Emergencies (35) Stress, Psychological (31) Lung Injury (30) Neoplasms (30) Inflammation (29) Stress Disorders, Post-Traumatic (29) Wounds and Injuries (29) Hypoxia (28) Thrombosis (28) Diabetes Mellitus (26) Disease (25) Respiratory Tract Diseases (25) Stress Disorders, Traumatic (25) Depressive Disorder (24) Acute Kidney Injury (22) Disease Progression (22) Lung Diseases (22) Mental Disorders (21) Burnout, Psychological (19) Olfaction Disorders (19) Respiration Disorders (19) Thromboembolism (19) Hypertension (18) Embolism (16) Arthritis (15) Blood Coagulation Disorders (15) Hemostatic Disorders (15) Pulmonary Embolism (15) Pulmonary Fibrosis (15) Lung Diseases, Interstitial (14) Stroke (14) Respiratory Aspiration (13) Diabetes Mellitus, Type 2 (12) Fibrosis (12) Arthritis, Rheumatoid (11) Influenza, Human (11) Rheumatic Diseases (11) Venous Thrombosis (11) Dyspnea (10) Burnout, Professional (9) Chronic Pain (9) Cognitive Dysfunction (9) Collagen Diseases (9) Diabetes Mellitus, Type 1 (9) Myocardial Infarction (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Problem Behavior (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Heart Failure (8) Infarction (8) Liver Diseases (8) Myocarditis (8) Parasomnias (8) RNA Virus Infections (8) Sclerosis (8) Sepsis (8) Convalescence (7) Depression, Postpartum (7) Dyssomnias (7) Heart Diseases (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Lung Diseases, Obstructive (7) Lymphopenia (7) Multiple Sclerosis (7) Pulmonary Valve Insufficiency (7) Shock (7) Frailty (6) Immunologic Deficiency Syndromes (6) Lung Neoplasms (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Neurologic Manifestations (6) Obesity (6) Pulmonary Disease, Chronic Obstructive (6) Autoimmune Diseases (5) Brain Diseases (5) Brain Injuries (5) Breast Neoplasms (5) Chronic Disease (5) Coronaviridae Infections (5) Cross Infection (5) Delirium (5) Disease Susceptibility (5) Disseminated Intravascular Coagulation (5) Fatigue (5) Feeding and Eating Disorders (5) HIV Infections (5) Immune System Diseases (5) Kidney Diseases (5) Kidney Failure, Chronic (5) Multiple Organ Failure (5) Occupational Stress (5) Parkinson Disease (5) Thrombophilia (5) Toxemia (5) Acquired Immunodeficiency Syndrome (4) Acute Coronary Syndrome (4) Anemia, Sickle Cell (4) Appendicitis (4) Arrhythmias, Cardiac (4) Arthritis, Psoriatic (4) Asymptomatic Diseases (4) Autism Spectrum Disorder (4) Carcinoma (4) Coinfection (4) Colonic Neoplasms (4) Coronary Artery Disease (4) Coronary Disease (4) Death (4) Embolism and Thrombosis (4) Headache (4) Heart Arrest (4) Leukemia (4) Musculoskeletal Pain (4) Mycobacterium Infections (4) Nervous System Diseases (4) Postoperative Complications (4) Signs and Symptoms, Respiratory (4) Substance-Related Disorders (4) Tuberculosis (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Adenoviridae Infections (3) Alcoholism (3) Asthma (3) Attention Deficit Disorder with Hyperactivity (3) Autistic Disorder (3) Bronchiectasis (3) Cardiomyopathies (3) Chilblains (3) Colorectal Neoplasms (3) Cystic Fibrosis (3) Deglutition Disorders (3) Digestive System Diseases (3) Dysgeusia (3) Ganglion Cysts (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Head and Neck Neoplasms (3) Hemorrhage (3) Hypertension, Pulmonary (3) Ischemia (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Migraine Disorders (3) (3) Myeloproliferative Disorders (3) Myocardial Ischemia (3) Obesity, Morbid (3) Pancreatic Neoplasms (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psoriasis (3) Pulmonary Edema (3) Rare Diseases (3) Renal Insufficiency, Chronic (3) Rheumatic Fever (3) Sjogren's Syndrome (3) Sleep Initiation and Maintenance Disorders (3) Sleep Wake Disorders (3) Spinal Cord Injuries (3) Spondylarthritis (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Acute Disease (2) Ageusia (2) Alcohol Drinking (2) Alopecia (2) Amyotrophic Lateral Sclerosis (2) Anorexia (2) Anorexia Nervosa (2) Arteritis (2) Asymptomatic Infections (2) Atrial Fibrillation (2) Bacteremia (2) Behcet Syndrome (2) Bipolar Disorder (2) Brain Injuries, Traumatic (2) Carcinoma, Renal Cell (2) Child Development Disorders, Pervasive (2) Cholangiocarcinoma (2) Cholangitis (2) Clinical Deterioration (2) Compassion Fatigue (2) Congenital Abnormalities (2) Conjunctivitis (2) (2) Dementia (2) Depressive Disorder, Major (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Encephalitis (2) Endocrine System Diseases (2) Eye Diseases (2) Fever (2) Fibromyalgia (2) Fractures, Bone (2) Fractures, Stress (2) Genetic Predisposition to Disease (2) Glucose Metabolism Disorders (2) Heart Defects, Congenital (2) Hematologic Diseases (2) Hepatitis C (2) Hypersensitivity (2) Hypothermia (2) Idiopathic Pulmonary Fibrosis (2) Infertility, Male (2) Intestinal Diseases (2) Jaundice (2) Leukemia, Lymphoid (2) Liver Cirrhosis (2) Lymphoma, Mantle-Cell (2) Macular Edema (2) Motor Neuron Disease (2) Mouth Diseases (2) Multiple Myeloma (2) Myelodysplastic Syndromes (2) Myositis (2) Neoplasm Metastasis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neuroendocrine Tumors (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Obstetric Labor, Premature (2) Oral Manifestations (2) (2) Overweight (2) Pediatric Obesity (2) Pneumonia, Pneumocystis (2) Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) Premature Birth (2) Psychological Trauma (2) Psychotic Disorders (2) Rectal Neoplasms (2) Renal Insufficiency (2) ST Elevation Myocardial Infarction (2) Sarcopenia (2) (2) Scleroderma, Systemic (2) Seizures (2) Shock, Septic (2) Sleep Apnea Syndromes (2) Sleep Apnea, Obstructive (2) Stillbirth (2) Suicide (2) Thyroid Diseases (2) Uterine Cervical Neoplasms (2) Vision Disorders (2) Vision, Low (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alpha 1-Antitrypsin Deficiency (1) Altitude Sickness (1) Alzheimer Disease (1) Amblyopia (1) Anemia, Aplastic (1) Aneurysm (1) Angina Pectoris (1) Ankle Fractures (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Atherosclerosis (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Bacterial Infections (1) Barotrauma (1) Behavior, Addictive (1) Binge-Eating Disorder (1) Blister (1) Body Weight (1) Body Weight Changes (1) Bradycardia (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Bulimia Nervosa (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Cardiovascular Abnormalities (1) Cataract (1) Cellulitis (1) Central Nervous System Neoplasms (1) Cerebral Hemorrhage (1) Cerebral Palsy (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Cognition Disorders (1) Colitis (1) Colitis, Ulcerative (1) Colonic Diseases (1) (1) Common Cold (1) Communicable Diseases, Emerging (1) Communication Disorders (1) Consciousness Disorders (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronavirus Infect (1) (1) Crohn Disease (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Caries (1) Depressive Disorder, Treatment-Resistant (1) Dermatitis (1) Developmental Disabilities (1) DiGeorge Syndrome (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) (1) Emergence Delirium (1) Emphysema (1) Endocarditis (1) Endometrial Neoplasms (1) Endometriosis (1) Endophthalmitis (1) Endotoxemia (1) Epilepsy (1) Esophageal Neoplasms (1) Esophageal and Gastric Varices (1) Eye Infections (1) Facial Pain (1) Facies (1) Familial Mediterranean Fever (1) Fatigue Syndrome, Chronic (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fractures, Closed (1) Gambling (1) Gastroenteritis (1) Gastroesophageal Reflux (1) Gestational Weight Gain (1) Glioblastoma (1) Headache Disorders, Secondary (1) Healthcare-Associated Pneumonia (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Systolic (1) Hemoglobinopathies (1) Hemophilia A (1) Hepatitis (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Humeral Fractures (1) Hyperaldosteronism (1) Hyperglycemia (1) Hyperkinesis (1) Hyperphosphatemia (1) Hyperplasia (1) Hypertension, Pregnancy-Induced (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypotension (1) Hypoventilation (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infecti (1) Infertility, Female (1) Intellectual Disability (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Kidney Neoplasms (1) Laryngeal Neoplasms (1) Latent Tuberculosis (1) Leukemia, Myeloid, Acute (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Liver Neoplasms (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Macular Degeneration (1) Malnutrition (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolic Syndrome (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Mobility Limitation (1) Monoclonal Gammopathy of Undetermined Significance (1) Mood Disorders (1) Mouth, Edentulous (1) Movement Disorders (1) Mucocutaneous Lymph Node Syndrome (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophies (1) Myalgia (1) Mycoses (1) Myocardial Reperfusion Injury (1) Myofascial Pain Syndromes (1) Necrosis (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Nervous System Neoplasms (1) Neurocognitive Disorders (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Nutrition Disorders (1) Obsessive Behavior (1) Oligospermia (1) Orbital Cellulitis (1) Osteoarthritis (1) Osteoarthritis, Hip (1) Osteoarthritis, Knee (1) Osteochondritis (1) Otitis Media with Effusion (1) Ovarian Neoplasms (1) Pain, Intractable (1) Pancreatitis (1) Paramyxoviridae Infections (1) Paraproteinemias (1) Paresis (1) Parkin (1) Perinatal Death (1) Periodontal Diseases (1) Periodontitis (1) Pharyngeal Diseases (1) Pneumon (1) Pneumonia, Bacterial (1) Pre-Eclampsia (1) Prediabetic State (1) Pregnancy in Diabetics (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Pulmonary Heart Disease (1) Purpura, Thrombocytopenic, Idiopathic (1) Recurrence (1) Reperfusion Injury (1) Resp (1) Respiratory Distress Sy (1) Respiratory Syncytial Virus Infections (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis (1) Scleroderma, Localized (1) (1) Shock, Cardiogenic (1) Shoulder Fractures (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Somatoform Disorders (1) Spondylitis (1) Spondylitis, Ankylosing (1) Sprains and Strains (1) Status Epilepticus (1) Stomach Neoplasms (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Suicidal Ideation (1) Superinfection (1) Synovial Cyst (1) Tachycardia (1) Tachycardia, Ventricular (1) Tachypnea (1) Testicular Neoplasms (1) Thalassemia (1) Thoracic Diseases (1) Thrombocytopenia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tobacco Use Disorder (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Tuberculosis, Pulmonary (1) Urinary Tract Infections (1) Urogenital Neoplasms (1) Urologic Diseases (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Vascular Diseases (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Weight Loss (1) Yellow Fever (1) beta-Thalassemia (1)

D001168: Arthritis

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (31)


Name (Synonyms) Correlation
drug481 Blood sampling Wiki 0.46
drug502 Breath Biopsy face masks with removable filters and fitted PVA strip Wiki 0.37
drug500 Breath Biopsy Wiki 0.26
Name (Synonyms) Correlation
drug3014 Serological analyses to be lead on a pre-existing biobank Wiki 0.26
drug1914 Maltodextrin Wiki 0.26
drug3186 Stools Wiki 0.26
drug484 Blood test for IgG antibodies against SARS-CoV-2 Wiki 0.26
drug3928 oropharyngeal swabs Wiki 0.26
drug3709 blood tests Wiki 0.26
drug493 Botulinum Neurotoxin Wiki 0.26
drug627 COVID-19 test Wiki 0.26
drug482 Blood sampling (venesection) Wiki 0.26
drug2689 Questionnaire by phone call Wiki 0.26
drug501 Breath Biopsy Analysis Wiki 0.26
drug3172 Standardised questionnaires Wiki 0.26
drug53 40ml blood sample Wiki 0.26
drug3067 Skin biopsy Wiki 0.26
drug3398 Traditional antirheumatic drugs Wiki 0.26
drug1523 Hydroxychloroquine/Chloroquine Wiki 0.26
drug618 COVID-19 infection Wiki 0.26
drug494 Bovine Lactoferrin Wiki 0.26
drug499 Brazilian Green Propolis Extract (EPP-AF) Wiki 0.26
drug3357 Throat swab Wiki 0.18
drug483 Blood test Wiki 0.18
drug2115 Nasopharyngeal swabs Wiki 0.18
drug2274 Online Questionnaire Wiki 0.18
drug3978 questionnaire assesment Wiki 0.12
drug2113 Nasopharyngeal swab Wiki 0.10
drug3132 Standard care Wiki 0.09
drug1472 Hydroxychloroquine Wiki 0.03
drug2448 Placebo Wiki 0.01

Correlated MeSH Terms (19)


Name (Synonyms) Correlation
D001172 Arthritis, Rheumatoid NIH 0.86
D015535 Arthritis, Psoriatic NIH 0.52
D025241 Spondylarthritis NIH 0.45
Name (Synonyms) Correlation
D001167 Arteritis NIH 0.37
D008180 Lupus Erythematosus, Systemic NIH 0.32
D012859 Sjogren's Syndrome NIH 0.30
D011111 Polymyalgia Rheumatica NIH 0.30
D013700 Giant Cell Arteritis NIH 0.30
D013166 Spondylitis NIH 0.26
D013167 Spondylitis, Ankylosing NIH 0.26
D001171 Arthritis, Juvenile NIH 0.26
D003095 Collagen Diseases NIH 0.26
D012216 Rheumatic Diseases NIH 0.23
D001327 Autoimmune Diseases NIH 0.23
D059350 Chronic Pain NIH 0.09
D003141 Communicable Diseases NIH 0.04
D007239 Infection NIH 0.02
D045169 Severe Acute Respiratory Syndrome NIH 0.01
D018352 Coronavirus Infections NIH 0.01

Correlated HPO Terms (6)


Name (Synonyms) Correlation
HP:0001369 Arthritis HPO 0.97
HP:0001370 Rheumatoid arthritis HPO 0.82
HP:0012089 Arteritis HPO 0.37
Name (Synonyms) Correlation
HP:0002725 Systemic lupus erythematosus HPO 0.32
HP:0002960 Autoimmunity HPO 0.23
HP:0012532 Chronic pain HPO 0.09

Clinical Trials

Navigate: Correlations   HPO

There are 15 clinical trials


1 COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.

NCT04335747
Conditions
  1. Rheumatoid Arthritis
  2. Psoriatic Arthritis
  3. Axial Spondyloarthritis
  4. Systemic Lupus Erythematosus
  5. Giant Cell Arteritis
Interventions
  1. Other: COVID-19 infection
MeSH:Arthritis Arthritis, Psoriatic Rheumatic Diseases Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Collagen Diseases
HPO:Arteritis Arthritis Polyarticular arthritis Systemic lupus erythematosus

Primary Outcomes

Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease

Measure: Disease activity

Time: Last registration of disease activity in the medical journal before admission/inclusion

Secondary Outcomes

Description: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.

Measure: Immune modulating treatments

Time: Current immune modulating treatments at admission/inclusion

Description: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups

Measure: Biomarkers

Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1
2 Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease

This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.

NCT04345159
Conditions
  1. SARS-CoV-2
  2. Systemic Lupus Erythematosus
  3. Rheumatoid Arthritis
  4. Sjogren's Syndrome
  5. Psoriatic Arthritis
Interventions
  1. Other: Questionnaire by phone call
MeSH:Arthritis Arthritis, Psoriatic Sjogren's Syndrome Lupus Erythematosus, Systemic Autoimmune Diseases
HPO:Arthritis Autoimmunity Polyarticular arthritis Systemic lupus erythematosus

Primary Outcomes

Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.

Measure: Adjusted Odds Ratio

Time: 4 months after inclusion
3 IMPACT RAPPORT: IMPact of Antimalarials on Covid Infections: a Case Control sTudy of RAPPORT

This study aims to evaluate the experience of Alberta patients with inflammatory arthritis who participate in the the RAPPORT-ONTRAAC registry during the COVID-19 pandemic, specifically comparing the experience of those taking anti-malarial medications compared to those who do not. This registry includes approximately 2500 northern Alberta patients with inflammatory arthritis who receive highly complex therapies which may be associated with side effects. This program of data collection and research has been evaluating the effectiveness and safety as well as associated health care costs of rheumatoid and psoriatic arthritis patients since 2004. The principle investigators are based at the University of Alberta while the co-investigators are academic rheumatologists at the University of Alberta. The registry has approximately 900 patients taking anti-malarials combined with their complex therapies and ~ 1500 not on anti-malarials in combination with their complex therapies. We aim to perform a case control study evaluating the impact of anti-malarial drugs (eg. hydroxychloroquine and chloroquine) on the development of COVID-19 compared to those patients who are not on anti-malarial drugs over the next 6-12 months. In addition to frequent e-mail surveys screening for the clinical symptoms of COVID-19 and understanding their concomitant arthritis medication use, we will compare the healthcare outcomes of both groups of arthritis patients with and without COVID-19 for the duration of the pandemic. This information will provide critical information beyond an anecdotal level on whether or not anti-malarials truly provide a protective benefit against COVID-19 or reduce the severity of infection. A blood sample from all participants (Covid-19 positive and negative) will be drawn approximately six months into the study for measurement of antibodies to Covid-19 and possible blood types and HLA alleles. Additionally, this study will be linked to another study "Persistence of SARS-Cov2 in immunocompromised patients" which will specifically evaluate COVID-19 serology and nasopharyngeal swab findings in the subset of patients who develop COVID-19.

NCT04347798
Conditions
  1. Covid-19 Infection
  2. Rheumatoid Arthritis
  3. Psoriatic Arthritis
  4. Hydroxychloroquine
Interventions
  1. Other: Hydroxychloroquine/Chloroquine
MeSH:Infection Communicable Diseases Arthritis Arthritis, Rheumatoid Arthritis, Psoriatic
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: Number of patients developing signs and symptoms of Covid-19 or other infections

Measure: Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group

Time: 12 months

Secondary Outcomes

Description: Number of patients developing Covid-19 infection

Measure: Incidence of Covid-19 infection in the anti-malarial group compared to the non-anti-malarial group

Time: 12 months

Description: Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action

Measure: Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action

Time: 12 months

Other Outcomes

Description: Quantitative measurement of Covid-19 serology to understand possible differences in degree of immune response adjusted for anti-malarial and/or biologic exposure

Measure: Quantification of Covid-19 antibodies in anti-malarial vs non-anti-malarial groups of inflammatory arthritis patients

Time: 6 months
4 Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak

Clinical data about psychological impact of quarantine are well studied in transient event or more prolonged situation like jail incarceration. In recent metaanalysis, psychological impact of quarantine was well documented in a specific population during first SARS epidemy. Even after the end of quarantine several patients were still with symptom of avoiding mainly agoraphobia, frequent hand washing and a carefull return to normal life COVID-19 infection is already associated with psychological symptom like anxiety, depression, sleep disorders and symptoms of acute stress However psychological impact of quarantine is on none in chronic painful inflammatory rheumatism in France. The prevalence of rheumatoid arthritis is 0.5% of the population with frequent comorbidity such as anxiety and depression. During the quarantine secondary to COVID-19 pandemic it's possible to evaluated the psychological impact of adult RA patients. The present study is an "emergency" being realize before the end of the quarantine.

NCT04351399
Conditions
  1. Sars-CoV2
  2. Rheumatic Diseases
  3. Rheumatoid Arthritis
  4. Chronic Pain
Interventions
  1. Other: questionnaire assesment
MeSH:Arthritis Arthritis, Rheumatoid Rheumatic Diseases Collagen Diseases Chronic Pain
HPO:Arthritis Chronic pain Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Measure: Frequency of RA patients with emotional impact (feeling of isolation)

Time: maximum 1 week from baseline on

Secondary Outcomes

Description: Self reported questionnaire with questions to assess the characteristic,intensity of pain on quality of life, and consumption of analgesic.

Measure: self-reported questionnaire for painful

Time: maximum 1 week from baseline on
5 Immune Cells and the Coronavirus for Inflammatory Arthritis

A team at the University of Manchester are developing a test that tcould be helpful in detecting immunity to the Coronavirus (which causes the COVID-19 disease) in participants with inflammatory arthritis. It is based on a flu assay has already developed; the team will replace the flu antigen with a Coronavirus antigen to see if it is effective. This project aims to develop a test to see if people who have had the virus have developed immunity to it. This could help to predict who might or might not get the disease a second time, who should stay at home to be protected from potential infection or who will not develop any symptoms, even if exposed to the virus. When vaccination trials against the Coronavirus will be launched, this test could also help to see if the vaccine is effective.

NCT04363047
Conditions
  1. SARS Virus
Interventions
  1. Other: 40ml blood sample
MeSH:Arthritis
HPO:Arthritis Polyarticular arthritis

Primary Outcomes

Description: the prevalence and abundance of CD4+ T lymphocytes specifically recognizing SARS-CoV-2 in COVID-19 patients with inflammatory arthritis, in pre- and post-infection samples; in patients without COVID-19 and in healthy volunteers with or without COVID-19. Correlation of these cells with COVID-19 severity.

Measure: Prevalence and abundance of CD4+ T lymphocytes

Time: 2 years
6 Antimalarial and Covid 19 in Rheumatoid Arthritis

The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action differ them from glucocorticoids and nonsteroidal antiinflammatory agents. Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately active rheumatoid arthritis (RA).

NCT04389320
Conditions
  1. Rheumatoid Arthritis
Interventions
  1. Drug: Hydroxychloroquine
MeSH:Arthritis Arthritis, Rheumatoid
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: serum level

Measure: immunoglobulin mesurement

Time: 1 month
7 Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.

NCT04393233
Conditions
  1. Rheumatoid Arthritis
  2. COVID
MeSH:Arthritis Arthritis, Rheumatoid
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD

Measure: Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis

Time: 1 Day
8 Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe

The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.

NCT04397237
Conditions
  1. COVID-19
  2. Systemic Lupus Erythematosus
  3. Sjogren's Syndrome
  4. Axial Spondyloarthritis
  5. Rheumatoid Arthritis
  6. Giant Cell Arteritis
MeSH:Arthritis Arthritis, Rheumatoid Sjogren's Syndrome Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Autoimmune Diseases
HPO:Arteritis Arthritis Autoimmunity Polyarticular arthritis Rheumatoid arthritis Systemic lupus erythematosus

Primary Outcomes

Description: ELISA tests for COVID-19 antibodies

Measure: COVID-19 seroconversion

Time: 1 day, during routine blood collection

Description: Case report form filled by the health professional

Measure: COVID-19 infection

Time: During medical visit or phone consultation, up to 2 hours

Secondary Outcomes

Description: Descriptive analysis for each disease's rate

Measure: Seroconversion rate by disease

Time: 1 day, during routine blood collection

Description: Descriptive analysis for each country's rate

Measure: Penetration across Europe

Time: 1 day, during routine blood collection

Description: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.

Measure: COVID-19 severity

Time: During medical visit, up to 1 hour

Description: Descriptive analysis for overall and COVID-19-linked mortality rates

Measure: COVID-19 mortality rate

Time: During contact with family members, up to 1 hour

Description: Case report form filled by the health professional

Measure: COVID-19 impact on immunomodulatory treatment

Time: During medical visit, up to 1 hour

Description: Case report form filled by the patient

Measure: Patient-reported flares

Time: During medical visit, up to 1 hour

Description: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.

Measure: Patient's fears towards COVID-19

Time: During medical visit, up to 1 hour

Description: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.

Measure: Patient's beliefs in their medicines towards COVID-19

Time: During medical visit, up to 1 hour
9 Impact of the Rheumatoid Factor on Serological Testing Performance for Covid-19 in Rheumatoid Arthritis Patients

Due to the Covid-19 worldwide outbreak, fragile patients with immune diseases, notably rheumatoid arthritis (RA), have to be even more specifically and carefully followed-up. However, it has been shown that false postive serological results often occured while detecting antibodies directed against SARS-CoV-2 in patients with positive rheumatodoid factor (RF). The investigators propose here to investigated this issue. Therefore, the investigators will test three different immunoassays on this specific population. The investigators aim to establish these assays specificity and the levels of RF for which there is a risk of anti-SARS-CoV-2 false positivity and thus ensure a better follow-up of RA patients. The RF isotype will be analysed to determine whether there is a correlation and the impact of the presence of anti-CCP (citrullinated cyclic antipeptide antibodies) will be studied and assessed.

NCT04407559
Conditions
  1. COVID-19
  2. Rheumatoid Arthritis
Interventions
  1. Other: Serological analyses to be lead on a pre-existing biobank
MeSH:Arthritis Arthritis, Rheumatoid
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: Evaluate the false positive results rate when using each one of the three SARS-CoV-2 serology tests in patients with rheumatoid factor plasma levels, so as to define the specificity of these tests in this RA population. all serum samples will be tested by the 3 different immunoassays. The RF plasma levels have already been measured (routine exam) and are written in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the question.

Measure: Evaluate the false positive results rate

Time: 4 months

Secondary Outcomes

Description: Characterize the RF isotype (IgG, IgM or IgA) associated with the false positivity of the test.all serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions

Measure: Characterize the RF isotype (IgG, IgM or IgA) associated

Time: 4 months

Description: Determine the influence of RA on the false positivity rate in subjects with negative RF titer. All serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions

Measure: Determine the influence of RA on the false positivity rate in subjects

Time: 4 months

Description: Assess the influence of the presence of anti-CCP on the false positivity of the SARS-CoV-2 test : all serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions.

Measure: Assess the influence of the presence of anti-CCP on the false positivity of the SARS-CoV-2 test

Time: 4 months

Description: Assess the relation between the RF plasma levels and the false positivity of the SARS-CoV-2 test : all serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions.

Measure: Assess the relation between the RF plasma levels and the false positivity of the SARS-CoV-2 test

Time: 4 months
10 Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Juvenile Idiopathic Arthritis is concerns by these fears (the patient and their parents). Patients are treated by several classes of immunomodulatory drugs, including non-steroidal anti-inflammatory drugs, corticosteroids and disease modifying anti-rheumatic drugs. The present study will characterize this issue by defining the proportion of patients whose usual treatment of Juvenile Idiopathic Arthritis has been modified in relation to the actual sanitary crisis, and also to return to school.

NCT04407923
Conditions
  1. Juvenile Idiopathic Arthritis
  2. COVID 19
  3. Treatment
MeSH:Arthritis Arthritis, Juvenile
HPO:Arthritis Polyarticular arthritis

Primary Outcomes

Description: Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD

Measure: Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis

Time: 1 Day
11 Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients: A Retrospective, Case-control Study

Rheumatoid arthritis (RA) patients have an underlying immune deficiency and typically treated with immunosuppressive drugs, which may increase the risk of COVID-19 infection. Hydroxychloroquine (HCQ) has been found to possess antiviral activity against COVID-19. Thus, the aim of this study to investigate the ability of HCQ to reduce the risk of COVID-19 among RA patients.

NCT04434118
Conditions
  1. Rheumatoid Arthritis
  2. COVID
Interventions
  1. Drug: Traditional antirheumatic drugs
MeSH:Arthritis Arthritis, Rheumatoid
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: Realtion between hydroxychloroquine use and COVID-19 infection

Measure: The risk of COVID-19 infection among RA patients

Time: 12 week

Secondary Outcomes

Description: Number of cases and number of hospitalization days

Measure: The incidence of hospitalization for Covid-19 patients.

Time: 12 week
12 Seroprevalence and Clinical Expression of SARS-CoV-2 Infection in Patients With Chronic Inflammatory Rheumatisms and Impact of Immuno-suppressive Drugs on the Persistence of Anti-SARS-CoV2 Antibodies During Two Years of Follow-up

A better understanding of the different phenotypes of COVID 19 in patients with inflammatory rheumatisms, and the persitence of antibodies against SARS CoV-2 in these patients under immunosuppressive drugs are required to propose appropriated recommendations for these patients in order to guide the strategy of vaccination in this immune-depressed population who is not immunized.

NCT04530682
Conditions
  1. Rheumatoid Arthritis
MeSH:Arthritis Arthritis, Rheumatoid
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: Variation of anti-SARS-CoV2 antibodies titers between baseline

Measure: Seroprevalence of COVID-19 in patients with inflammatory rheumatisms

Time: 6 months

Description: Variation of anti-SARS-CoV2 antibodies titers between baseline

Measure: Seroprevalence of COVID-19 in patients with inflammatory rheumatisms

Time: 12 months

Secondary Outcomes

Description: Coagulation factors in patients with inflammatory rheumatisms compared to health professionals

Measure: Clinical expression of COVID-19 compared to health professionals : phenotypes, thrombo-embolic events and stress repercussion

Time: 6 months

Description: Coagulation factors in patients with inflammatory rheumatisms compared to health professionals

Measure: Clinical expression of COVID-19 compared to health professionals : phenotypes, thrombo-embolic events and stress repercussion

Time: 12 months

Description: Coagulation factors in patients with inflammatory rheumatisms compared to health professionals

Measure: Clinical expression of COVID-19 compared to health professionals : phenotypes, thrombo-embolic events and stress repercussion

Time: 24 months
13 Study of the Viral Load and Humoral and Cellular B and T Responses in Patients With Rheumatoid Arthritis and Spondyloarthritis Under Immunosuppressive Treatments

The purpose of this study is to assess whether immunosuppressive therapies used by patients with chronic inflammatory rheumatic diseases have an impact on the viral load and the humoral and cellular responses during viral infection with SarSCoV2, compared to members of their family cluster infected with the same viral strain.

NCT04584541
Conditions
  1. Spondyloarthritis
  2. Rheumatoid Arthritis
  3. Covid19
Interventions
  1. Biological: blood tests
  2. Biological: Nasopharyngeal swabs
  3. Biological: Stools
MeSH:Arthritis Arthritis, Rheumatoid Spondylarthritis
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA

Measure: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs

Time: up to Day 30

Description: Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA

Measure: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs

Time: between Day 30 and Day 90

Measure: Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood

Time: up to Day 30

Measure: Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood

Time: between Day 30 and Day 90

Measure: Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood

Time: 6 Months

Measure: Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood

Time: 12 Months

Measure: Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood

Time: 24 Months

Measure: Isolation and characterization of B and T lymphocytes in blood

Time: up to Day 30

Measure: Isolation and characterization of B and T lymphocytes in blood

Time: between Day 30 and Day 90

Measure: Isolation and characterization of B and T lymphocytes in blood

Time: 6 Months

Measure: Isolation and characterization of B and T lymphocytes in blood

Time: 12 Months

Measure: Isolation and characterization of B and T lymphocytes in blood

Time: 24 Months
14 Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases

The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. The proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with CoV-2-SARS infection. Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive screening in routine care of patients with chronic inflammatory rheumatism with serological testing

NCT04655612
Conditions
  1. COVID-19
  2. SARS-CoV Infection
  3. Rheumatoid Arthritis
  4. Spondyloarthritis
  5. Ankylosing Spondylitis
  6. Psoriatic Arthritis
MeSH:Infection Communicable Diseases Spondylitis Coronavirus Infections Severe Acute Respiratory Syndrome Arthritis Arthritis, Rheumatoid Arthritis, Psoriatic Spondylitis, Ankylosing Rheumatic Diseases Spondylarthritis Collagen Diseases
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis

Measure: Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis

Time: 1 day

Secondary Outcomes

Description: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.

Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.

Time: 1 day

Description: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease

Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease

Time: 1 day

Description: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics

Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics

Time: 1 day
15 Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients : ProCOVRA

COVID-19 is an infectious disease caused by SARS-CoV2 virus. The objective of our study is to analyze the progression and the severity of COVID-19 in patients with RA. Indeed, few data are available on this subject, and this would allow us to improve management of COVID-19 in these potential at-risk patients.

NCT04679272
Conditions
  1. Covid19
  2. Rheumatoid Arthritis
MeSH:Arthritis Arthritis, Rheumatoid
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: Proportion of hospitalized patients in RA group or control group. From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

Measure: Hospitalization rates for COVID-19

Time: 1 day

Secondary Outcomes

Description: Proportion of patients transferred in critical care for COVID-19 or deaths due to COVID-19 From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

Measure: Critical care transfer rate for COVID-19 and death due to COVID-19

Time: 1 day

Description: Type and severity of patients pulmonary comorbidities and treatment by corticosteroids or DMARDs in RA group From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

Measure: Pulmonary comorbidities, corticosteroids or DMARDs use

Time: 1 day

Description: Patients demographics, comorbidities, COVID-19 clinical presentation From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

Measure: Age, gender, co-morbidities, clinical presentation, associated treatments

Time: 1 day

HPO Nodes


HP:0001369: Arthritis
Genes 273
NLRP3 PSMB4 ACP5 SLC37A4 PTPN22 MIR140 LMNA HGD COL1A1 MMP13 FRZB MMP14 COL9A3 NTRK1 ARVCF PTPN22 LMX1B HPRT1 GBA HLA-C PFKM ABCG8 TNFRSF1A IL2RB RREB1 NLRP3 HPGD TF BTK JMJD1C COPA COL2A1 PIK3CD EXT1 COMP TBX1 IL12B STAT4 TNFRSF11B IL10 TBX1 GJB6 LRP6 IL2RA TRPV4 MUC1 WIPF1 COMP MMP13 GJB2 PSTPIP1 RNASEH2C HPRT1 DCLRE1C HIRA GP1BB TRAPPC2 IRF5 IL6 ATP7B EPCAM CLCN7 SEC24C HJV IL36RN COL3A1 KIF7 SLC37A4 GHR NLRP12 STAT4 SPTA1 MLX COL11A1 SLC40A1 HPGD PTPN2 SMAD3 IGLL1 COL9A1 PTPN22 SLC22A4 FGFR3 COL2A1 UMOD CCN6 IDS TCF3 PRPS1 IGHM MYH14 CD79A PIK3R1 FASLG COL1A1 HNF1B CD79B NLRP3 ASAH1 HLA-DRB1 PRKCD ANKRD55 HLA-B COL5A1 CCR6 DNAJB11 COL2A1 MATN3 IL23R KNSTRN GLA F8 PTPN22 RAG1 RNF168 COL5A1 PTPN2 COL11A2 TREX1 TFR2 COL11A2 SLC26A2 UMOD SLC12A3 FAS CD247 EPB42 VPS13A EXT2 NOD2 COL11A2 CLCN7 NOD2 HGD ZNF687 CLCNKB FCGR2B TLR4 IL2RA MVK COMP CTLA4 TREX1 MEFV CAV1 IFIH1 ANKRD55 WAS AGA MATN3 NLRP3 CFI FAS COL9A2 SAMHD1 UFD1 SH3KBP1 HNF1B ASAH1 LACC1 G6PC1 TNFRSF1A MEFV TRAPPC2 CASP10 ANKH STAT4 UFSP2 TRPV4 SMAD3 COL2A1 MYD88 GPR101 IRAK1 C4A HPRT1 ZMPSTE24 ACAN STAT4 CCR1 GCH1 UBAC2 BTK HFE CD247 AIP HPGD MEFV ACAN UFSP2 RNASEH2B FAS PSMB9 MTHFD1 COL2A1 GDF5 PSTPIP1 SLC4A1 RAG2 PADI4 OCRL PHEX COL9A1 COL9A3 MIF ANKH ERAP1 KIF22 SCARB2 SPP1 CANT1 MMP2 ADA2 LBR HLA-DRB1 PTPN22 FOXP3 PRPS1 CCN6 ADAR IL2RB NLRP3 GNAS COMP COL2A1 HPRT1 FBN1 KLRC4 DNASE1 ACP5 PHEX HLA-B RNASEH2A LEMD3 HOXD10 SPTB BTK HNF4A DNASE1L3 RASGRP1 ATP7B IL10 ASPN HLA-DRB1 PRKCD MVK LRRC8A IL12A-AS1 APOE ACAN LRBA AEBP1 CCN2 CIITA COMT BLNK SEC61A1 COL9A2 ANK1 COL5A2 CTLA4 PRG4 MATN3 IL12A CD244 TGFB3 FCGR2A F9 NFKBIL1 SLCO2A1 TRPS1 HLA-B IDS
Protein Mutations 4
A147T N363S R620W V600E

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


HP:0001369: Arthritis
Genes 273
NLRP3 PSMB4 ACP5 SLC37A4 PTPN22 MIR140 LMNA HGD COL1A1 MMP13 FRZB MMP14 COL9A3 NTRK1 ARVCF PTPN22 LMX1B HPRT1 GBA HLA-C PFKM ABCG8 TNFRSF1A IL2RB RREB1 NLRP3 HPGD TF BTK JMJD1C COPA COL2A1 PIK3CD EXT1 COMP TBX1 IL12B STAT4 TNFRSF11B IL10 TBX1 GJB6 LRP6 IL2RA TRPV4 MUC1 WIPF1 COMP MMP13 GJB2 PSTPIP1 RNASEH2C HPRT1 DCLRE1C HIRA GP1BB TRAPPC2 IRF5 IL6 ATP7B EPCAM CLCN7 SEC24C HJV IL36RN COL3A1 KIF7 SLC37A4 GHR NLRP12 STAT4 SPTA1 MLX COL11A1 SLC40A1 HPGD PTPN2 SMAD3 IGLL1 COL9A1 PTPN22 SLC22A4 FGFR3 COL2A1 UMOD CCN6 IDS TCF3 PRPS1 IGHM MYH14 CD79A PIK3R1 FASLG COL1A1 HNF1B CD79B NLRP3 ASAH1 HLA-DRB1 PRKCD ANKRD55 HLA-B COL5A1 CCR6 DNAJB11 COL2A1 MATN3 IL23R KNSTRN GLA F8 PTPN22 RAG1 RNF168 COL5A1 PTPN2 COL11A2 TREX1 TFR2 COL11A2 SLC26A2 UMOD SLC12A3 FAS CD247 EPB42 VPS13A EXT2 NOD2 COL11A2 CLCN7 NOD2 HGD ZNF687 CLCNKB FCGR2B TLR4 IL2RA MVK COMP CTLA4 TREX1 MEFV CAV1 IFIH1 ANKRD55 WAS AGA MATN3 NLRP3 CFI FAS COL9A2 SAMHD1 UFD1 SH3KBP1 HNF1B ASAH1 LACC1 G6PC1 TNFRSF1A MEFV TRAPPC2 CASP10 ANKH STAT4 UFSP2 TRPV4 SMAD3 COL2A1 MYD88 GPR101 IRAK1 C4A HPRT1 ZMPSTE24 ACAN STAT4 CCR1 GCH1 UBAC2 BTK HFE CD247 AIP HPGD MEFV ACAN UFSP2 RNASEH2B FAS PSMB9 MTHFD1 COL2A1 GDF5 PSTPIP1 SLC4A1 RAG2 PADI4 OCRL PHEX COL9A1 COL9A3 MIF ANKH ERAP1 KIF22 SCARB2 SPP1 CANT1 MMP2 ADA2 LBR HLA-DRB1 PTPN22 FOXP3 PRPS1 CCN6 ADAR IL2RB NLRP3 GNAS COMP COL2A1 HPRT1 FBN1 KLRC4 DNASE1 ACP5 PHEX HLA-B RNASEH2A LEMD3 HOXD10 SPTB BTK HNF4A DNASE1L3 RASGRP1 ATP7B IL10 ASPN HLA-DRB1 PRKCD MVK LRRC8A IL12A-AS1 APOE ACAN LRBA AEBP1 CCN2 CIITA COMT BLNK SEC61A1 COL9A2 ANK1 COL5A2 CTLA4 PRG4 MATN3 IL12A CD244 TGFB3 FCGR2A F9 NFKBIL1 SLCO2A1 TRPS1 HLA-B IDS
Protein Mutations 4
A147T N363S R620W V600E

Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook